NASDAQ:CELG - Celgene Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$79.13 -0.01 (-0.01 %)
(As of 06/22/2018 03:12 PM ET)
Previous Close$79.40
Today's Range$78.73 - $79.86
52-Week Range$74.13 - $147.17
Volume321,788 shs
Average Volume6.56 million shs
Market Capitalization$57.82 billion
P/E Ratio11.54
Dividend YieldN/A
Beta1.45
Celgene logoCelgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. to advance a PD-1 Inhibitor program for solid tumor cancers. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; and Prothena Corporation plc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CELG
CUSIP15102010
Phone908-673-9000

Debt

Debt-to-Equity Ratio3.92
Current Ratio2.53
Quick Ratio2.36

Price-To-Earnings

Trailing P/E Ratio11.54
Forward P/E Ratio10.37
P/E Growth0.5

Sales & Book Value

Annual Sales$13.00 billion
Price / Sales4.41
Cash Flow$7.5578 per share
Price / Cash10.47
Book Value$8.79 per share
Price / Book9.00

Profitability

EPS (Most Recent Fiscal Year)$6.84
Net Income$2.94 billion
Net Margins20.73%
Return on Equity72.92%
Return on Assets17.48%

Miscellaneous

Employees7,467
Outstanding Shares724,830,000

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Shares of Celgene split before market open on Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were payable to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene announced that its board has approved a stock buyback plan on Thursday, May 24th 2018, which allows the company to repurchase $3,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 5.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's management believes its stock is undervalued.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) released its quarterly earnings data on Friday, May, 4th. The biopharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.09. The biopharmaceutical company earned $3.54 billion during the quarter, compared to analyst estimates of $3.47 billion. Celgene had a return on equity of 72.92% and a net margin of 20.73%. The company's revenue was up 19.4% on a year-over-year basis. During the same period last year, the company earned $1.68 earnings per share. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene updated its FY18 earnings guidance on Friday, May, 4th. The company provided earnings per share guidance of $8.45 for the period, compared to the Thomson Reuters consensus estimate of $8.45. The company issued revenue guidance of $14.8 billion, compared to the consensus revenue estimate of $14.81 billion.

What price target have analysts set for CELG?

33 Wall Street analysts have issued 1-year target prices for Celgene's stock. Their forecasts range from $85.00 to $166.00. On average, they expect Celgene's share price to reach $124.1321 in the next twelve months. View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:
  • 1. Canaccord Genuity analysts commented, "We expect median Progression Free Survival (PFS) > 10 months for the initial bb2121 dose escalation cohort previously reported at ASH 2017, based on 71% progression free at 9 months. Importantly, we believe PFS data could easily exceed our estimate and the 8.8 months PFS seen for pomalidomide + daratumumab + dexamethasone in Phase 1b. Duration of follow-up key for new n=21 patient cohort Investors should carefully consider the median follow-up time for the new n=21 patient bb2121 cohort with no BCMA expression cutoff, since Complete Responses improve over time. We will consider the initial bb2121 data presented at AACR in 2016, where a 78% ORR and 22% CR rate was seen. Importantly, we expect a very rapid Overall Response Rate, as seen for initial bb2121 data." (5/30/2018)
  • 2. According to Zacks Investment Research, "Celgene’s first-quarter results were encouraging as the company beat on both sales and earnings. Revlimid sales were impressive yet again along with Pomalyst and Otezla. Celgene’s key growth driver, Revlimid, continues to drive revenues. However, a late stage study on Revlimid in combination with Rituxan failed. Celgene suffered yet another setback when it received Refusal to File letter from the FDA regarding its New Drug Application for multiple sclerosis candidate ozanimod. Celgene was on the look-out of new deals and acquisitions given a lacklustre 2017 and the Juno acquisition was on the same track. We are positive on the acquisition. The bluebird deal will further bolster Celgene’s presence in the CAR-T space. The company has a few data read-outs lined up for the rest of the year on key drugs. Shares have underperformed the industry in the last six months." (5/10/2018)
  • 3. Cann analysts commented, "Celgene announced today that John Weiland has been elected to its board of directors. Mr. Weiland was most recently President and Chief Operating Officer of C.R. Bard, Inc. Prior to this role, Mr. Weiland held the position of Group President of Bard and had global responsibility for Bard Medical Division, Bard Urological Division, Davol Inc., Bard Endoscopic Technologies Division and Bard’s Worldwide Manufacturing Operations. We believe Mr. Weiland will bring significant commercial and operational experience to the Celgene Board." (2/15/2018)
  • 4. Cantor Fitzgerald analysts commented, "CELG’s current CEO, Mark Alles, will assume the role of Chairman of the Board, following the retirement of current COB Robert Hugin, effective February 5th, which follows his departure as President in early 2016." (1/29/2018)

Are investors shorting Celgene?

Celgene saw a increase in short interest in May. As of May 31st, there was short interest totalling 34,342,932 shares, an increase of 179.2% from the May 15th total of 12,301,961 shares. Based on an average daily trading volume, of 8,715,018 shares, the days-to-cover ratio is currently 3.9 days. Approximately 4.8% of the company's shares are sold short. View Celgene's Current Options Chain.

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 59)
  • Mr. Peter N. Kellogg BSE, MBA, Exec. VP, CFO & Chief Accounting Officer (Age 62)
  • Mr. Rupert J. Vessey, Exec. VP and Pres of Research & Early Devel. (Age 53)
  • Mr. Patrick E. Flanigan III, Corp. VP of Investor Relations
  • Mr. Gerald F. Masoudi, Exec. VP, Gen. Counsel & Corp. Sec. (Age 50)

Has Celgene been receiving favorable news coverage?

Press coverage about CELG stock has been trending somewhat positive on Friday, according to Accern. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Celgene earned a media sentiment score of 0.17 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.71 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Celgene's major shareholders?

Celgene's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.51%), Edgewood Management LLC (1.65%), Northern Trust Corp (1.33%), Franklin Resources Inc. (1.28%), American Century Companies Inc. (0.60%) and Legal & General Group Plc (0.49%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Mark J Alles, Michael A Friedman, Michael D Casey, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Which institutional investors are selling Celgene stock?

CELG stock was sold by a variety of institutional investors in the last quarter, including Polen Capital Management LLC, Carmignac Gestion, Massachusetts Financial Services Co. MA, Franklin Resources Inc., Northern Trust Corp, OppenheimerFunds Inc., Eaton Vance Management and Atlantic Trust Group LLC. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Robert J Hugin and Terrie Curran. View Insider Buying and Selling for Celgene.

Which institutional investors are buying Celgene stock?

CELG stock was bought by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., Natixis, Edgewood Management LLC, Westfield Capital Management Co. LP, Commerzbank Aktiengesellschaft FI, Mackay Shields LLC, American Century Companies Inc. and Darrell & King LLC. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene and Mark J Alles. View Insider Buying and Selling for Celgene.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $78.97.

How big of a company is Celgene?

Celgene has a market capitalization of $57.82 billion and generates $13.00 billion in revenue each year. The biopharmaceutical company earns $2.94 billion in net income (profit) each year or $6.84 on an earnings per share basis. Celgene employs 7,467 workers across the globe.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]


MarketBeat Community Rating for Celgene (CELG)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  1,760 (Vote Outperform)
Underperform Votes:  568 (Vote Underperform)
Total Votes:  2,328
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.